small molecule

MULTAQ

DRONEDARONE HYDROCHLORIDE

Loss of exclusivityJune 2031latest FDA-listed patent expiry
CompanySANOFI AVENTIS US LLC

Drug detail

Brand nameMULTAQ
Active ingredientDRONEDARONE HYDROCHLORIDE
StrengthEQ 400MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusRX

Listed patents

PatentExpiresType
8602215June 2031use U-1473
8410167April 2029use U-1388
9107900April 2029use U-1726

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

MULTAQ patent cliff — loss of exclusivity June 2031 | CliffBio